Dr. Garon on Antiangiogenic Agents in Lung Cancer

Edward B. Garon, MD
Published: Thursday, Aug 31, 2017



Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses antiangiogenic agents in patients with lung cancer.

Enthusiasm for antiangiogenic agents has waned although the data have not changed, states Garon. There is a benefit in overall survival, progression-free survival, and an objective response rate when antiangiogenic therapies are added in combination with other agents.
 


Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses antiangiogenic agents in patients with lung cancer.

Enthusiasm for antiangiogenic agents has waned although the data have not changed, states Garon. There is a benefit in overall survival, progression-free survival, and an objective response rate when antiangiogenic therapies are added in combination with other agents.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x